Expansion of Sartorius Stedim Cellca

• Biopharma provider purchases property in Science Park III of Ulm • Laboratory and office facility to be constructed on the site by 2019 Göttingen/Laupheim, December 14, 2016 – Sartorius Stedim Cellca based near Ulm in southern Germany, continues on the growth track. At the end of November, the company in its eleventh year since More

Sartorius Stedim Biotech Opens New Bioanalytical Testing Laboratory

New services to enable U.S. biopharmaceutical companies to accelerate development of biosimilar. Goettingen, Germany | Boston, MA, USA – November 10, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new bioanalytical and biosafety testing laboratory yesterday in the major biotech hub of Boston, Massachusetts. This dedicated bioanalytical laboratory More

Sartorius Stedim BioOutsource Introduces New Released N-Glycan Assay

In-depth profiling of IgG glycosylation coupled with ADCC assays enables generation of robust biosimilar comparability data   Glasgow, UK – July 7, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, announced the launched of a new Released N-Glycan Assay for the in-depth profiling of IgG glycosylation. This new physico-chemical assay, More

Sartorius Stedim BioOutsource Appoints Technical Sales Specialist in India

To help Indian researchers access a portfolio of excellent services from BioOutsource and Cellca Glasgow, UK – June 29, 2016: Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, is pleased to announce that its subsidiary BioOutsource has appointed Ravin Mehta as Technical Sales Specialist to enable customers to have access to More

New Sartorius Stedim BioOutsource Microsite Goes Live

Cellca’s Cell Line and Upstream Process Development Services Now Integrated Glasgow, UK – June 14, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced that its subsidiary BioOutsource launched an updated website to spotlight Sartorius Stedim Cellca’s cell line and upstream process development services for the biopharmaceutical industry. The new More

Sartorius Stedim BioOutsource set to double Glasgow workforce in 2016

To Continue Building Analytical Capabilities for Testing Drugs and Vaccines Glasgow, UK – April 27, 2016: Sartorius Stedim BioOutsource, a leading provider of contract testing services to the biopharmaceutical industry, is pleased to announce that it is looking to almost double the scientific workforce at its Glasgow facilities in 2016. The new staff will help More

New Webinar: Optimizing Analytics for Biosimilars

How Providing Comprehensive Data Can Accelerate Drug Development Glasgow, UK – April 21, 2016: Sartorius Stedim BioOutsource today announced that its scientific experts will be presenting a live webinar about optimizing biosimilar analysis on Thursday, June 2, at 3 pm BST, 10 am EDT. The webinar is essential listening for researchers who want to understand More

Sartorius Stedim BioOutsource Introduces Assays for Testing Biosimilarity of Three Leading Biologics

New ready-to-use assays enable quick and simple generation of precise biosimilar comparability data Glasgow, UK – March 22, 2016: Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, presents a range of ready-to-use assays for testing Actemra, Stelara and Lucentis biosimilars. The new assays, launched by SSB’s subsidiary Sartorius Stedim BioOutsource, will More

New Video on ADCC Assays from BioOutsource

Rapidly reveals the factors to consider when using ADCC assays for producing precise biosimilar comparability data Glasgow, UK – November 17, 2015: Sartorius Stedim Biotech (SSB) BioOutsource today announced a new video is now available on-line explaining how to overcome the issues associated with using antibody-dependent cell-mediated cytotoxicity (ADCC) assays. The bite-sized video outlines the More

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.